News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Concert Pharmaceuticals, Inc. Presents Preclinical Results Demonstrating CTP-499, a Novel Treatment for Diabetic Kidney Disease, Ameliorated Renal Fibrosis and Inflammation In Vivo


11/2/2012 9:02:42 AM

SAN DIEGO--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today presented preclinical results which demonstrated CTP-499’s anti-fibrotic and anti-inflammatory properties in vivo. These findings were presented in a poster at the American Society of Nephrology’s (ASN) Kidney Week 2012. CTP-499 is currently in Phase 2 clinical development in patients with diabetic nephropathy, the leading cause of chronic kidney disease (CKD) worldwide.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES